Huntington's Disease and its therapeutic target genes: a global functional profile based on the HD Research Crossroads database

BMC Neurology

Volumn 12, Issue , 2012, Pages

  Kalathur, Ravi Kiran R ^a   Hernández Prieto, Miguel A ^a   Futschik, Matthias E ^a  

^a UNIVERSITY OF ALGARVE   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 5; EPIDERMAL GROWTH FACTOR RECEPTOR; HISTONE DEACETYLASE 3; HUNTINGTIN; METABOTROPIC RECEPTOR 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1BETA; WNT PROTEIN;

ARTICLE; BIOINFORMATICS; CALCIUM SIGNALING; CELL CYCLE; DNA MODIFICATION; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE IDENTIFICATION; GENE MUTATION; GENE TARGETING; GENETIC DATABASE; GENETIC LINKAGE; HUMAN; HUNTINGTON CHOREA; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; RNA SPLICING; SIGNAL TRANSDUCTION;

CHROMOSOME MAPPING; DATABASES, PROTEIN; GENE TARGETING; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HUNTINGTON DISEASE; INTERNATIONALITY; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEOME;

EID: 84862759032     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/1471-2377-12-47     Document Type: Article

References (97)

1. Kassubek J, Juengling FD, Kioschies T, Henkel K, Karitzky J, Kramer B, Ecker D, Andrich J, Saft C, Kraus P, et al. Topography of cerebral atrophy in early Huntington's disease: a voxel based morphometric MRI study. J Neurol Neurosurg Psychiatry 2004, 75:213-220. 1738932, 14742591.
2. Politis M, Pavese N, Tai YF, Tabrizi SJ, Barker RA, Piccini P. Hypothalamic involvement in Huntington's disease: an in vivo PET study. Brain 2008, 131:2860-2869. 10.1093/brain/awn244, 18829696.
3. Andrew SE, Goldberg YP, Kremer B, Telenius H, Theilmann J, Adam S, Starr E, Squitieri F, Lin B, Kalchman MA, et al. The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease. Nat Genet 1993, 4:398-403. 10.1038/ng0893-398, 8401589.
4. Andrew SE, Goldberg YP, Theilmann J, Zeisler J, Hayden MR. A CCG repeat polymorphism adjacent to the CAG repeat in the Huntington disease gene: implications for diagnostic accuracy and predictive testing. Hum Mol Genet 1994, 3:65-67. 10.1093/hmg/3.1.65, 8162053.
5. Farrer LA, Cupples LA, Wiater P, Conneally PM, Gusella JF, Myers RH. The normal Huntington disease (HD) allele, or a closely linked gene, influences age at onset of HD. Am J Hum Genet 1993, 53:125-130. 1682222, 8317477.
6. Rubinsztein DC, Barton DE, Davison BC, Ferguson-Smith MA. Analysis of the huntingtin gene reveals a trinucleotide-length polymorphism in the region of the gene that contains two CCG-rich stretches and a correlation between decreased age of onset of Huntington's disease and CAG repeat number. Hum Mol Genet 1993, 2:1713-1715. 10.1093/hmg/2.10.1713, 8268927.
7. Snell RG, MacMillan JC, Cheadle JP, Fenton I, Lazarou LP, Davies P, MacDonald ME, Gusella JF, Harper PS, Shaw DJ. Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease. Nat Genet 1993, 4:393-397. 10.1038/ng0893-393, 8401588.
8. Vonsattel JP, DiFiglia M. Huntington disease. J Neuropathol Exp Neurol 1998, 57:369-384. 10.1097/00005072-199805000-00001, 9596408.
9. Zuccato C, Valenza M, Cattaneo E. Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol Rev 2010, 90:905-981. 10.1152/physrev.00041.2009, 20664076.
10. Harjes P, Wanker EE. The hunt for huntingtin function: interaction partners tell many different stories. Trends Biochem Sci 2003, 28:425-433. 10.1016/S0968-0004(03)00168-3, 12932731.
11. Wexler NS, Lorimer J, Porter J, Gomez F, Moskowitz C, Shackell E, Marder K, Penchaszadeh G, Roberts SA, Gayan J, et al. Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. Proc Natl Acad Sci U S A 2004, 101:3498-3503. 373491, 14993615.
12. Gusella JF, MacDonald ME. Huntington's disease: the case for genetic modifiers. Genome Med 2009, 1:80. 10.1186/gm80, 2768966, 19725930.
13. Nollen EA, Garcia SM, van Haaften G, Kim S, Chavez A, Morimoto RI, Plasterk RH. Genome-wide RNA interference screen identifies previously undescribed regulators of polyglutamine aggregation. Proc Natl Acad Sci U S A 2004, 101:6403-6408. 10.1073/pnas.0307697101, 404057, 15084750.
14. Wada T, Honda M, Minami I, Tooi N, Amagai Y, Nakatsuji N, Aiba K. Highly efficient differentiation and enrichment of spinal motor neurons derived from human and monkey embryonic stem cells. PLoS One 2009, 4:e6722. 10.1371/journal.pone.0006722, 2726947, 19701462.
15. Gatchel JR, Zoghbi HY. Diseases of unstable repeat expansion: mechanisms and common principles. Nat Rev Genet 2005, 6:743-755.
16. Munoz-Sanjuan I, Bates GP. The importance of integrating basic and clinical research toward the development of new therapies for Huntington disease. J Clin Invest 2011, 121:476-483. 10.1172/JCI45364, 3026740, 21285520.
17. Walker FO. Huntington's disease. Lancet 2007, 369:218-228. 10.1016/S0140-6736(07)60111-1, 17240289.
18. Hochberg Y, Benjamini Y. More powerful procedures for multiple significance testing. Stat Med 1990, 9:811-818. 10.1002/sim.4780090710, 2218183.
19. Hodges A, Strand AD, Aragaki AK, Kuhn A, Sengstag T, Hughes G, Elliston LA, Hartog C, Goldstein DR, Thu D, et al. Regional and cellular gene expression changes in human Huntington's disease brain. Hum Mol Genet 2006, 15:965-977. 10.1093/hmg/ddl013, 16467349.
20. Strand AD, Baquet ZC, Aragaki AK, Holmans P, Yang L, Cleren C, Beal MF, Jones L, Kooperberg C, Olson JM, Jones KR. Expression profiling of Huntington's disease models suggests that brain-derived neurotrophic factor depletion plays a major role in striatal degeneration. J Neurosci 2007, 27:11758-11768. 10.1523/JNEUROSCI.2461-07.2007, 17959817.
21. Kuhn A, Goldstein DR, Hodges A, Strand AD, Sengstag T, Kooperberg C, Becanovic K, Pouladi MA, Sathasivam K, Cha JH, et al. Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. Hum Mol Genet 2007, 16:1845-1861. 10.1093/hmg/ddm133, 17519223.
22. Lee JM, Ivanova EV, Seong IS, Cashorali T, Kohane I, Gusella JF, MacDonald ME. Unbiased gene expression analysis implicates the huntingtin polyglutamine tract in extra-mitochondrial energy metabolism. PLoS Genet 2007, 3:e135. 10.1371/journal.pgen.0030135, 1950164, 17708681.
23. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004, 5:R80. 10.1186/gb-2004-5-10-r80, 545600, 15461798.
24. Li JL, Hayden MR, Almqvist EW, Brinkman RR, Durr A, Dode C, Morrison PJ, Suchowersky O, Ross CA, Margolis RL, et al. A genome scan for modifiers of age at onset in Huntington disease: the HD MAPS study. Am J Hum Genet 2003, 73:682-687. 10.1086/378133, 1180695, 12900792.
25. Gayan J, Brocklebank D, Andresen JM, Alkorta-Aranburu G, Zameel Cader M, Roberts SA, Cherny SS, Wexler NS, Cardon LR, Housman DE. Genomewide linkage scan reveals novel loci modifying age of onset of Huntington's disease in the Venezuelan HD kindreds. Genet Epidemio 2008, 32:445-453.
26. Frank S. Tetrabenazine: the first approved drug for the treatment of chorea in US patients with Huntington disease. Neuropsychiatr Dis Treat 2010, 6:657-665. 2951749, 20957126.
27. DiFiglia M, Sena-Esteves M, Chase K, Sapp E, Pfister E, Sass M, Yoder J, Reeves P, Pandey RK, Rajeev KG, et al. Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proc Natl Acad Sci U S A 2007, 104:17204-17209. 10.1073/pnas.0708285104, 2040405, 17940007.
28. Coyle JT, Schwarcz R. Lesion of striatal neurones with kainic acid provides a model for Huntington's chorea. Nature 1976, 263:244-246. 10.1038/263244a0, 8731.
29. Bence NF, Sampat RM, Kopito RR. Impairment of the ubiquitin-proteasome system by protein aggregation. Science 2001, 292:1552-1555. 10.1126/science.292.5521.1552, 11375494.
30. DiFiglia M, Sapp E, Chase KO, Davies SW, Bates GP, Vonsattel JP, Aronin N. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 1997, 277:1990-1993. 10.1126/science.277.5334.1990, 9302293.
31. Waelter S, Boeddrich A, Lurz R, Scherzinger E, Lueder G, Lehrach H, Wanker EE. Accumulation of mutant huntingtin fragments in aggresome-like inclusion bodies as a result of insufficient protein degradation. Mol Biol Cell 2001, 12:1393-1407. 34592, 11359930.
32. Tydlacka S, Wang CE, Wang X, Li S, Li XJ. Differential activities of the ubiquitin-proteasome system in neurons versus glia may account for the preferential accumulation of misfolded proteins in neurons. J Neurosci 2008, 28:13285-13295. 10.1523/JNEUROSCI.4393-08.2008, 2662777, 19052220.
33. Bennett EJ, Shaler TA, Woodman B, Ryu KY, Zaitseva TS, Becker CH, Bates GP, Schulman H, Kopito RR. Global changes to the ubiquitin system in Huntington's disease. Nature 2007, 448:704-708. 10.1038/nature06022, 17687326.
34. Steffan JS, Kazantsev A, Spasic-Boskovic O, Greenwald M, Zhu YZ, Gohler H, Wanker EE, Bates GP, Housman DE, Thompson LM. The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc Natl Acad Sci U S A 2000, 97:6763-6768. 10.1073/pnas.100110097, 18731, 10823891.
35. Vis JC, Schipper E, de Boer-van Huizen RT, Verbeek MM, de Waal RM, Wesseling P, ten Donkelaar HJ, Kremer B. Expression pattern of apoptosis-related markers in Huntington's disease. Acta Neuropathol 2005, 109:321-328. 10.1007/s00401-004-0957-5, 15668790.
36. Zhang Y, Ona VO, Li M, Drozda M, Dubois-Dauphin M, Przedborski S, Ferrante RJ, Friedlander RM. Sequential activation of individual caspases, and of alterations in Bcl-2 proapoptotic signals in a mouse model of Huntington's disease. J Neurochem 2003, 87:1184-1192. 10.1046/j.1471-4159.2003.02105.x, 14622098.
37. Vis JC, Verbeek MM, de Waal RM, ten Donkelaar HJ, Kremer B. The mitochondrial toxin 3-nitropropionic acid induces differential expression patterns of apoptosis-related markers in rat striatum. Neuropathol Appl Neurobiol 2001, 27:68-76. 10.1046/j.0305-1846.2001.00305.x, 11299004.
38. Caviston JP, Ross JL, Antony SM, Tokito M, Holzbaur EL. Huntingtin facilitates dynein/dynactin-mediated vesicle transport. Proc Natl Acad Sci U S A 2007, 104:10045-10050. 10.1073/pnas.0610628104, 1891230, 17548833.
39. Sahlender DA, Roberts RC, Arden SD, Spudich G, Taylor MJ, Luzio JP, Kendrick-Jones J, Buss F. Optineurin links myosin VI to the Golgi complex and is involved in Golgi organization and exocytosis. J Cell Biol 2005, 169:285-295. 10.1083/jcb.200501162, 2171882, 15837803.
40. Pal A, Severin F, Lommer B, Shevchenko A, Zerial M. Huntingtin-HAP40 complex is a novel Rab5 effector that regulates early endosome motility and is up-regulated in Huntington's disease. J Cell Biol 2006, 172:605-618. 10.1083/jcb.200509091, 2063679, 16476778.
41. Panov AV, Gutekunst CA, Leavitt BR, Hayden MR, Burke JR, Strittmatter WJ, Greenamyre JT. Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat Neurosci 2002, 5:731-736.
42. Lim D, Fedrizzi L, Tartari M, Zuccato C, Cattaneo E, Brini M, Carafoli E. Calcium homeostasis and mitochondrial dysfunction in striatal neurons of Huntington disease. J Biol Chem 2008, 283:5780-5789.
43. Zhang S, Binari R, Zhou R, Perrimon N. A genomewide RNA interference screen for modifiers of aggregates formation by mutant Huntingtin in Drosophila. Genetics 2010, 184:1165-1179. 10.1534/genetics.109.112516, 2865916, 20100940.
44. Faber PW, Barnes GT, Srinidhi J, Chen J, Gusella JF, MacDonald ME. Huntingtin interacts with a family of WW domain proteins. Hum Mol Genet 1998, 7:1463-1474. 10.1093/hmg/7.9.1463, 9700202.
45. Passani LA, Bedford MT, Faber PW, McGinnis KM, Sharp AH, Gusella JF, Vonsattel JP, MacDonald ME. Huntingtin's WW domain partners in Huntington's disease post-mortem brain fulfill genetic criteria for direct involvement in Huntington's disease pathogenesis. Hum Mol Genet 2000, 9:2175-2182. 10.1093/hmg/9.14.2175, 10958656.
46. Jiang YJ, Che MX, Yuan JQ, Xie YY, Yan XZ, Hu HY. Interaction with polyglutamine-expanded huntingtin alters cellular distribution and RNA processing of huntingtin yeast two-hybrid protein A (HYPA). J Biol Chem 2011, 286:25236-25245. 10.1074/jbc.M110.216333, 3137094, 21566141.
47. Curtis MA, Penney EB, Pearson AG, van Roon-Mom WM, Butterworth NJ, Dragunow M, Connor B, Faull RL. Increased cell proliferation and neurogenesis in the adult human Huntington's disease brain. Proc Natl Acad Sci U S A 2003, 100:9023-9027. 10.1073/pnas.1532244100, 166431, 12853570.
48. Batista CM, Kippin TE, Willaime-Morawek S, Shimabukuro MK, Akamatsu W, van der Kooy D. A progressive and cell non-autonomous increase in striatal neural stem cells in the Huntington's disease R6/2 mouse. J Neurosci 2006, 26:10452-10460. 10.1523/JNEUROSCI.2850-06.2006, 17035529.
49. Lorincz MT, Zawistowski VA. Expanded CAG repeats in the murine Huntington's disease gene increases neuronal differentiation of embryonic and neural stem cells. Mol Cell Neurosci 2009, 40:1-13. 10.1016/j.mcn.2008.06.004, 2666278, 18625318.
50. Gil JM, Leist M, Popovic N, Brundin P, Petersen A. Asialoerythropoietin is not effective in the R6/2 line of Huntington's disease mice. BMC Neurosci 2004, 5:17. 10.1186/1471-2202-5-17, 434499, 15134587.
51. Herrup K, Yang Y. Cell cycle regulation in the postmitotic neuron: oxymoron or new biology?. Nat Rev Neurosci 2007, 8:368-378.
52. Rideout HJ, Wang Q, Park DS, Stefanis L. Cyclin-dependent kinase activity is required for apoptotic death but not inclusion formation in cortical neurons after proteasomal inhibition. J Neurosci 2003, 23:1237-1245.
53. Majdzadeh N, Wang L, Morrison BE, Bassel-Duby R, Olson EN, D'Mello SR. HDAC4 inhibits cell-cycle progression and protects neurons from cell death. Dev Neurobiol 2008, 68:1076-1092. 10.1002/dneu.20637, 2722383, 18498087.
54. Choo YS, Johnson GV, MacDonald M, Detloff PJ, Lesort M. Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release. Hum Mol Genet 2004, 13:1407-1420. 10.1093/hmg/ddh162, 15163634.
55. Orr AL, Li S, Wang CE, Li H, Wang J, Rong J, Xu X, Mastroberardino PG, Greenamyre JT, Li XJ. N-terminal mutant huntingtin associates with mitochondria and impairs mitochondrial trafficking. J Neurosci 2008, 28:2783-2792. 10.1523/JNEUROSCI.0106-08.2008, 2652473, 18337408.
56. Landles C, Sathasivam K, Weiss A, Woodman B, Moffitt H, Finkbeiner S, Sun B, Gafni J, Ellerby LM, Trottier Y, et al. Proteolysis of mutant huntingtin produces an exon 1 fragment that accumulates as an aggregated protein in neuronal nuclei in Huntington disease. J Biol Chem 2010, 285:8808-8823. 10.1074/jbc.M109.075028, 2838303, 20086007.
57. DiFiglia M, Sapp E, Chase K, Schwarz C, Meloni A, Young C, Martin E, Vonsattel JP, Carraway R, Reeves SA, et al. Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons. Neuron 1995, 14:1075-1081. 10.1016/0896-6273(95)90346-1, 7748555.
58. Hughes A, Jones L. Huntingtin localisation studies - a technical review. PLoS Curr 2011, 3:RRN1211. 3037564, 21339845.
59. Okun E, Griffioen KJ, Lathia JD, Tang SC, Mattson MP, Arumugam TV. Toll-like receptors in neurodegeneration. Brain Res Rev 2009, 59:278-292. 10.1016/j.brainresrev.2008.09.001, 2679904, 18822314.
60. Song M, Jin J, Lim JE, Kou J, Pattanayak A, Rehman JA, Kim HD, Tahara K, Lalonde R, Fukuchi K. TLR4 mutation reduces microglial activation, increases Abeta deposits and exacerbates cognitive deficits in a mouse model of Alzheimer's disease. J Neuroinflammation 2011, 8:92. 10.1186/1742-2094-8-92, 3169468, 21827663.
61. Richard KL, Filali M, Prefontaine P, Rivest S. Toll-like receptor 2 acts as a natural innate immune receptor to clear amyloid beta 1-42 and delay the cognitive decline in a mouse model of Alzheimer's disease. J Neurosci 2008, 28:5784-5793. 10.1523/JNEUROSCI.1146-08.2008, 18509040.
62. Ravikumar B, Vacher C, Berger Z, Davies JE, Luo S, Oroz LG, Scaravilli F, Easton DF, Duden R, O'Kane CJ, Rubinsztein DC. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet 2004, 36:585-595. 10.1038/ng1362, 15146184.
63. Tang TS, Tu H, Chan EY, Maximov A, Wang Z, Wellington CL, Hayden MR, Bezprozvanny I. Huntingtin and huntingtin-associated protein 1 influence neuronal calcium signaling mediated by inositol-(1,4,5) triphosphate receptor type 1. Neuron 2003, 39:227-239. 10.1016/S0896-6273(03)00366-0, 3220623, 12873381.
64. Tang TS, Slow E, Lupu V, Stavrovskaya IG, Sugimori M, Llinas R, Kristal BS, Hayden MR, Bezprozvanny I. Disturbed Ca2+ signaling and apoptosis of medium spiny neurons in Huntington's disease. Proc Natl Acad Sci U S A 2005, 102:2602-2607. 10.1073/pnas.0409402102, 548984, 15695335.
65. Apostol BL, Illes K, Pallos J, Bodai L, Wu J, Strand A, Schweitzer ES, Olson JM, Kazantsev A, Marsh JL, Thompson LM. Mutant huntingtin alters MAPK signaling pathways in PC12 and striatal cells: ERK1/2 protects against mutant huntingtin-associated toxicity. Hum Mol Genet 2006, 15:273-285.
66. Yamamoto A, Cremona ML, Rothman JE. Autophagy-mediated clearance of huntingtin aggregates triggered by the insulin-signaling pathway. J Cell Biol 2006, 172:719-731. 10.1083/jcb.200510065, 2063704, 16505167.
67. Caricasole A, Bakker A, Copani A, Nicoletti F, Gaviraghi G, Terstappen GC. Two sides of the same coin: Wnt signaling in neurodegeneration and neuro-oncology. Biosci Rep 2005, 25:309-327. 10.1007/s10540-005-2893-6, 16307379.
68. Kaytor MD, Orr HT. The GSK3 beta signaling cascade and neurodegenerative disease. Curr Opin Neurobiol 2002, 12:275-278. 10.1016/S0959-4388(02)00320-3, 12049933.
69. Lucas JJ, Hernandez F, Gomez-Ramos P, Moran MA, Hen R, Avila J. Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J 2001, 20:27-39. 10.1093/emboj/20.1.27, 140191, 11226152.
70. Berger Z, Ttofi EK, Michel CH, Matthieu Y, Pasco MY, Tenant S, Rubinsztein DC, O'Kane CJ. Lithium rescues toxicity of aggregate-prone proteins in Drosophila by perturbing Wnt pathway. Hum Mol Genet 2005, 14:3003-3011. 10.1093/hmg/ddi331, 16141285.
71. Gines S, Ivanova E, Seong IS, Saura CA, MacDonald ME. Enhanced Akt signaling is an early pro-survival response that reflects N-methyl-D-aspartate receptor activation in Huntington's disease knock-in striatal cells. J Biol Chem 2003, 278:50514-50522. 10.1074/jbc.M309348200, 14522959.
72. Busser J, Geldmacher DS, Herrup K. Ectopic cell cycle proteins predict the sites of neuronal cell death in Alzheimer's disease brain. J Neurosci 1998, 18:2801-2807.
73. Godin JD, Poizat G, Hickey MA, Maschat F, Humbert S. Mutant huntingtin-impaired degradation of beta-catenin causes neurotoxicity in Huntington's disease. EMBO J 2010, 29:2433-2445. 10.1038/emboj.2010.117, 2910267, 20531388.
74. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001, 2:127-137. 10.1038/35052073, 11252954.
75. Fischbach GD, Rosen KM. ARIA: a neuromuscular junction neuregulin. Annu Rev Neurosci 1997, 20:429-458. 10.1146/annurev.neuro.20.1.429, 9056721.
76. Mei L, Xiong WC. Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. Nat Rev Neurosci 2008, 9:437-452. 2682371, 18478032.
77. Sun Y, Savanenin A, Reddy PH, Liu YF. Polyglutamine-expanded huntingtin promotes sensitization of N-methyl-D-aspartate receptors via post-synaptic density 95. J Biol Chem 2001, 276:24713-24718. 10.1074/jbc.M103501200, 11319238.
78. Liu YF, Deth RC, Devys D. SH3 domain-dependent association of huntingtin with epidermal growth factor receptor signaling complexes. J Biol Chem 1997, 272:8121-8124. 10.1074/jbc.272.13.8121, 9079622.
79. Song C, Perides G, Liu YF. Expression of full-length polyglutamine-expanded Huntingtin disrupts growth factor receptor signaling in rat pheochromocytoma (PC12) cells. J Biol Chem 2002, 277:6703-6707. 10.1074/jbc.M110338200, 11733534.
80. Lievens JC, Rival T, Iche M, Chneiweiss H, Birman S. Expanded polyglutamine peptides disrupt EGF receptor signaling and glutamate transporter expression in Drosophila. Hum Mol Genet 2005, 14:713-724. 10.1093/hmg/ddi067, 15677486.
81. Bublil EM, Yarden Y. The EGF receptor family: spearheading a merger of signaling and therapeutics. Curr Opin Cell Biol 2007, 19:124-134. 10.1016/j.ceb.2007.02.008, 17314037.
82. Li JL, Hayden MR, Warby SC, Durr A, Morrison PJ, Nance M, Ross CA, Margolis RL, Rosenblatt A, Squitieri F, et al. Genome-wide significance for a modifier of age at neurological onset in Huntington's disease at 6q23-24: the HD MAPS study. BMC Med Genet 2006, 7:71. 10.1186/1471-2350-7-71, 1586197, 16914060.
83. Genin E, Feingold J, Clerget-Darpoux F. Identifying modifier genes of monogenic disease: strategies and difficulties. Hum Genet 2008, 124:357-368. 10.1007/s00439-008-0560-2, 2911473, 18784943.
84. Arning L, Monte D, Hansen W, Wieczorek S, Jagiello P, Akkad DA, Andrich J, Kraus PH, Saft C, Epplen JT. ASK1 and MAP2K6 as modifiers of age at onset in Huntington's disease. J Mol Med (Berl) 2008, 86:485-490.
85. Holbert S, Denghien I, Kiechle T, Rosenblatt A, Wellington C, Hayden MR, Margolis RL, Ross CA, Dausset J, Ferrante RJ, Neri C. The Gln-Ala repeat transcriptional activator CA150 interacts with huntingtin: neuropathologic and genetic evidence for a role in Huntington's disease pathogenesis. Proc Natl Acad Sci U S A 2001, 98:1811-1816. 10.1073/pnas.98.4.1811, 29339, 11172033.
86. Nishitoh H, Matsuzawa A, Tobiume K, Saegusa K, Takeda K, Inoue K, Hori S, Kakizuka A, Ichijo H. ASK1 is essential for endoplasmic reticulum stress-induced neuronal cell death triggered by expanded polyglutamine repeats. Genes Dev 2002, 16:1345-1355. 10.1101/gad.992302, 186318, 12050113.
87. Andresen JM, Gayan J, Cherny SS, Brocklebank D, Alkorta-Aranburu G, Addis EA, Cardon LR, Housman DE, Wexler NS. Replication of twelve association studies for Huntington's disease residual age of onset in large Venezuelan kindreds. J Med Genet 2007, 44:44-50. 2597910, 17018562.
88. Lin KT, Lu RM, Tarn WY. The WW domain-containing proteins interact with the early spliceosome and participate in pre-mRNA splicing in vivo. Mol Cell Biol 2004, 24:9176-9185. 10.1128/MCB.24.20.9176-9185.2004, 517884, 15456888.
89. Thomas EA, Coppola G, Desplats PA, Tang B, Soragni E, Burnett R, Gao F, Fitzgerald KM, Borok JF, Herman D, et al. The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice. Proc Natl Acad Sci U S A 2008, 105:15564-15569. 10.1073/pnas.0804249105, 2563081, 18829438.
90. Giampa C, Middei S, Patassini S, Borreca A, Marullo F, Laurenti D, Bernardi G, Ammassari-Teule M, Fusco FR. Phosphodiesterase type IV inhibition prevents sequestration of CREB binding protein, protects striatal parvalbumin interneurons and rescues motor deficits in the R6/2 mouse model of Huntington's disease. Eur J Neurosci 2009, 29:902-910. 10.1111/j.1460-9568.2009.06649.x, 19291221.
91. Perez-Navarro E, Akerud P, Marco S, Canals JM, Tolosa E, Arenas E, Alberch J. Neurturin protects striatal projection neurons but not interneurons in a rat model of Huntington's disease. Neuroscience 2000, 98:89-96. 10.1016/S0306-4522(00)00074-9, 10858615.
92. Ribeiro FM, Pires RG, Ferguson SS. Huntington's disease and Group I metabotropic glutamate receptors. Mol Neurobiol 2011, 43:1-11. 10.1007/s12035-010-8153-1, 21153060.
93. Schiefer J, Sprunken A, Puls C, Luesse HG, Milkereit A, Milkereit E, Johann V, Kosinski CM. The metabotropic glutamate receptor 5 antagonist MPEP and the mGluR2 agonist LY379268 modify disease progression in a transgenic mouse model of Huntington's disease. Brain Res 2004, 1019:246-254. 10.1016/j.brainres.2004.06.005, 15306259.
94. Weydt P, Soyal SM, Gellera C, Didonato S, Weidinger C, Oberkofler H, Landwehrmeyer GB, Patsch W. The gene coding for PGC-1alpha modifies age at onset in Huntington's Disease. Mol Neurodegener 2009, 4:3. 10.1186/1750-1326-4-3, 2630305, 19133136.
95. Lagace DC, Benavides DR, Kansy JW, Mapelli M, Greengard P, Bibb JA, Eisch AJ. Cdk5 is essential for adult hippocampal neurogenesis. Proc Natl Acad Sci U S A 2008, 105:18567-18571. 10.1073/pnas.0810137105, 2587597, 19017796.
96. Shelton SB, Johnson GV. Cyclin-dependent kinase-5 in neurodegeneration. J Neurochem 2004, 88:1313-1326. 10.1111/j.1471-4159.2003.02328.x, 15009631.
97. Luo S, Vacher C, Davies JE, Rubinsztein DC. Cdk5 phosphorylation of huntingtin reduces its cleavage by caspases: implications for mutant huntingtin toxicity. J Cell Biol 2005, 169:647-656. 10.1083/jcb.200412071, 2171695, 15911879.